Stocktoria
Crinetics Pharmaceuticals, Inc. CRNX
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2018-07-18
Crinetics Pharmaceuticals, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $7.7M | $1.0M | $4.0M | $4.7M | $1.1M |
| R&D expense | $332.1M | $240.2M | $168.5M | $130.2M | $84.3M |
| SG&A expense | $191.3M | $99.7M | $58.1M | — | — |
| Operating income | -$516.8M | -$338.9M | -$222.6M | -$167.9M | -$107.7M |
| Income tax | $180,000 | $0 | $0 | $0 | $0 |
| Net income | -$465.3M | -$298.4M | -$214.5M | -$163.9M | -$107.6M |
| EPS (diluted) | $-4.95 | $-3.69 | $-3.69 | $-3.15 | $-2.80 |
| Operating cash flow | -$377.9M | -$230.2M | -$168.6M | -$115.2M | -$88.6M |
| Free cash flow | -$383.7M | -$234.0M | -$173.3M | -$116.9M | -$89.0M |
| Cash & equivalents | $101.5M | $264.5M | $54.9M | $32.7M | $200.7M |
| Inventory | $2.0M | $0 | — | — | — |
| Total assets | $1.1B | $1.4B | $635.4M | $352.2M | $351.0M |
| Total liabilities | $134.2M | $109.8M | $96.2M | $35.8M | $19.1M |
| Shareholders' equity | $992.1M | $1.3B | $539.1M | $316.3M | $331.9M |
Source: SEC EDGAR filings · CIK 0001658247 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.